Nektar Therapeutics total revenue, net income and dynamics of changes in Euro today
The dynamics of Nektar Therapeutics net revenue grew by 185 000 € compared to the previous report. The dynamics of net income of Nektar Therapeutics has changed by -5 764 000 € in recent years. Here are the main financial indicators of Nektar Therapeutics. Schedule of the financial report of Nektar Therapeutics for today. The financial schedule of Nektar Therapeutics consists of three charts of the main financial indicators of the company: total assets, net revenue, net income. The financial report on the chart of Nektar Therapeutics allows you to clearly see the dynamics of fixed assets.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021
22 269 018.37 €
-16.211 % ↓
-115 801 344.01 €
-
31/12/2020
22 094 798.87 €
-30.713 % ↓
-110 373 229.58 €
-
30/09/2020
28 282 886.99 €
+2.79 % ↑
-102 258 368.02 €
-
30/06/2020
46 000 538.77 €
+109.51 % ↑
-75 338 160 €
-
31/12/2019
31 888 759.67 €
-
-106 827 627.43 €
-
30/09/2019
27 515 379.49 €
-
-93 050 161.42 €
-
30/06/2019
21 956 365.01 €
-
-103 504 272.84 €
-
31/03/2019
26 577 419.39 €
-
-111 605 950.22 €
-
Show:
to
Nektar Therapeutics financial report charts
The dates of the latest financial statements of Nektar Therapeutics: 31/03/2019, 31/12/2020, 31/03/2021. Dates and dates of financial statements are established by the laws of the country where the company operates. The latest date of the financial report of Nektar Therapeutics is 31/03/2021. Gross profit Nektar Therapeutics is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit Nektar Therapeutics is 17 891 000 €
Nektar Therapeutics quarterly report dates
Cost of revenue Nektar Therapeutics is the total cost of producing and distributing of products and services of a company. Cost of revenue Nektar Therapeutics is 5 756 000 € Total revenue Nektar Therapeutics refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue Nektar Therapeutics is 23 647 000 € Operating income Nektar Therapeutics is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Nektar Therapeutics is -109 392 000 €
Net income Nektar Therapeutics is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Nektar Therapeutics is -122 967 000 € Current assets Nektar Therapeutics is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Nektar Therapeutics is 1 099 051 000 € Total assets Nektar Therapeutics refers to the total amount of assets owned by a person or entity. Total assets Nektar Therapeutics is 1 456 561 000 €
31/03/2021
31/12/2020
30/09/2020
30/06/2020
31/12/2019
30/09/2019
30/06/2019
31/03/2019
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
16 848 437.76 €
18 023 713.05 €
23 037 467.60 €
40 563 948.80 €
26 248 756.67 €
22 875 490.56 €
17 230 778.92 €
21 454 424.51 €
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
5 420 580.61 €
4 071 085.82 €
5 245 419.39 €
5 436 589.97 €
5 640 003 €
4 639 888.93 €
4 725 586.09 €
5 122 994.88 €
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
22 269 018.37 €
22 094 798.87 €
28 282 886.99 €
46 000 538.77 €
31 888 759.67 €
27 515 379.49 €
21 956 365.01 €
26 577 419.39 €
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
-
-
-
-
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-103 017 399.98 €
-104 268 955.17 €
-97 044 967.35 €
-73 180 663.44 €
-103 249 064.83 €
-92 986 123.98 €
-104 503 445.19 €
-113 654 206.45 €
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-115 801 344.01 €
-110 373 229.58 €
-102 258 368.02 €
-75 338 160 €
-106 827 627.43 €
-93 050 161.42 €
-103 504 272.84 €
-111 605 950.22 €
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
90 032 868.11 €
71 156 892.12 €
94 672 757.04 €
90 816 384.97 €
103 937 467.26 €
93 276 175.90 €
100 469 086.72 €
111 559 805.60 €
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
125 286 418.35 €
126 363 754.04 €
125 327 854.34 €
119 181 202.21 €
135 137 824.50 €
120 501 503.47 €
126 459 810.20 €
140 231 625.84 €
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
1 035 006 001.08 €
1 071 690 034.64 €
983 027 379.31 €
1 084 839 368.74 €
1 338 712 016.85 €
1 486 821 189.05 €
1 503 765 682.96 €
1 403 280 586.88 €
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
1 371 682 820.85 €
1 449 098 430.61 €
1 420 751 506.18 €
1 501 939 674.31 €
1 862 129 533.81 €
1 966 602 843.74 €
1 977 299 920.73 €
2 040 234 594.41 €
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
141 413 493.23 €
187 361 295.29 €
52 588 860.86 €
54 814 161.76 €
90 747 638.90 €
76 490 833.85 €
80 446 087.25 €
100 531 240.70 €
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
333 270 593.21 €
118 045 479.45 €
106 763 589.99 €
93 907 132.99 €
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
538 634 883.56 €
564 643 499.84 €
510 885 014.05 €
501 913 180.92 €
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
28.93 %
28.71 %
25.84 %
24.60 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
936 553 151.86 €
1 014 517 788.47 €
1 102 744 424.19 €
1 183 035 126.48 €
1 323 494 650.26 €
1 401 959 343.90 €
1 466 414 906.69 €
1 538 321 413.50 €
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
-117 925 880.12 €
-64 641 083.01 €
-50 779 803.29 €
-76 181 005.67 €
Last revenue report of Nektar Therapeutics was 31/03/2021. According to last financial report total revenue in Nektar Therapeutics was 22 269 018.37 Euro and changed by -16.211% since last year. Net income in Nektar Therapeutics was -115 801 344.01 € in last quartal, net income changes to 0%.
Current cash Nektar Therapeutics - the sum of all of the cash a company has on the date of report. Current cash Nektar Therapeutics is 150 164 000 €
